Patients’ characteristics and differences between the two treatment groups after PS weighting.

<p>NYHA, New York Heart Association; ACS, acute coronary syndrome; CAD, coronary artery disease; CHF, chronic heart failure; BNP, B-type natriuretic peptide; renal disease, history of chronic renal failure; CPAP, continuous positive airway pressure; PCI, percutaneous coronary intervention ACEI/ARB, angiotensin-converting-enzyme inhibitors/angiotensin II receptor blockers. The systolic blood pressure (SBP), the heart rate (HR), the BNP, the serum creatinine and the left ventricular ejection fraction (LVEF) are presented as the median [IQR]. For categorical variables, the sum of the different categories might be inferior to the sample size because patients’ characteristics were analyzed from complete cases. The p values refer to the comparison of <i>inopressors alone</i> vs. <i>inopressors and inodilators</i>.</p

Kaplan-Meier representation of mortality: A.

<p>As evaluated in the original pooled datasets; <b>B.</b> as evaluated in the pooled datasets after PS weighting. (Combined regimen stands for <i>inopressors and inodilators</i>).</p

Subgroup PS-weighted analyses of the <i>inopressors and inodilators</i> vs. <i>inopressors alone</i> on short-term mortality.

<p>HR, hazard ratios; PS, propensity score; SBP, systolic blood pressure; ACS, acute coronary syndrome.</p

Patients’ characteristics and differences between the two treatment groups.

<p>NYHA, New York Heart Association; ACS, acute coronary syndrome; CAD, coronary artery disease; CHF, chronic heart failure; BNP, B-type natriuretic peptide; renal disease, history of chronic renal failure; CPAP, continuous positive airway pressure; PCI, percutaneous coronary intervention ACEI/ARB, angiotensin-converting-enzyme inhibitors/angiotensin II receptor blockers. The systolic blood pressure (SBP), the heart rate (HR), the BNP, the serum creatinine and the left ventricular ejection fraction (LVEF) are presented as the median [IQR]. For categorical variables, the sum of the different categories might be inferior to the sample size because patients’ characteristics were analyzed from complete cases. The p values refer to the comparison of <i>inopressors alone</i> vs. <i>inopressors and inodilators</i>.</p

Flowchart.

<p>Combined regimen stands for <i>inopressors and inodilators</i>; *patients excluded for missing data concerning the treatment regimen, the outcome or the length of hospital stay; ^$patients included in the final analysis.</p

Standard differences in the major baseline covariates between the two treatment regimens.

<p>NYHA, New York Heart Association; PCI, percutaneous intervention; IABP, intra-aortic balloon pump; CPAP, continuous positive airway pressure; HR, heart rate; BNP, B-type natriuretic peptide; ACS, acute coronary syndrome; CAD, coronary artery disease; CHF, chronic heart failure; ACEI/ARB, angiotensin-converting-enzyme inhibitors/angiotensin II receptor blockers; BB, beta blockers; SBP, systolic blood pressure; LVEF, left ventricular ejection fraction.</p

Additional file 1 of Statistical analysis plan for a randomized controlled trial examining pedometer-based walking intervention in patients with heart failure with reduced ejection fraction: the WATCHFUL trial

Additional file 1. Statistical Analysis Plan Checklist

Data_Sheet_1_Trends in outcomes of women with myocardial infarction undergoing primary angioplasty—Analysis of randomized trials.PDF

BackgroundSex- and gender-associated differences determine the disease response to treatment.AimThe study aimed to explore the hypothesis that progress in the management of STE-myocardial infarction (STEMI) overcomes the worse outcome in women.Methods and resultsWe performed an analysis of three randomized trials enrolling patients treated with primary PCI more than 10 years apart. PRAGUE-1,-2 validated the preference of transport for primary PCI over on-site fibrinolysis. PRAGUE-18 enrollment was ongoing at the time of the functional network of 24/7PCI centers, and the intervention was supported by intensive antiplatelets. The proportion of patients with an initial Killip ≥ 3 was substantially higher in the more recent study (0.6 vs. 6.7%, p = 0.004). Median time from symptom onset to the door of the PCI center shortened from 3.8 to 3.0 h, p 6 h was still significant (22.3 vs. 27.2% in PRAGUE-18). There was an increase in probability for an initial TIMI flow >0 in the later study (1.49 [1.0–2.23]), and also for an optimal procedural result (4.24 [2.12–8.49], p ConclusionThe prognosis of women with MI treated with primary PCI improved substantially with 24/7 regional availability of mechanical reperfusion, performance-enhancing technical progress, and intensive adjuvant antithrombotic therapy. A major modifiable hindrance to achieving this benefit in a broad population of women is the timely diagnosis by health professional services.</p

Predictive accuracy of scoring models for mortality during a three-year follow-up period.

<p>Predictive accuracy of scoring models for mortality during a three-year follow-up period.</p

Risk-scoring models and their components.

<p>*Recurrent MI, stroke, major bleed, CHF/shock, arrhythmia, renal failure.</p><p>BP—blood pressure, LBBB—left bundle branch block; PCI—percutaneous coronary intervention.</p><p>Risk-scoring models and their components.</p